Comparative Pharmacology
Head-to-head clinical analysis: KALYDECO versus SYMDEKO COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KALYDECO versus SYMDEKO COPACKAGED.
KALYDECO vs SYMDEKO (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein; increases the probability of CFTR channel opening by binding to the nucleotide-binding domain, thereby enhancing chloride transport in cells with defective CFTR gating mutations.
Symdeko is a combination of tezacaftor and ivacaftor. Tezacaftor is a CFTR corrector that facilitates the cellular processing and trafficking of the F508del-CFTR protein to the cell surface, while ivacaftor is a CFTR potentiator that increases the open probability of CFTR channels at the cell surface, thereby enhancing chloride transport in epithelial cells.
150 mg orally every 12 hours with fat-containing food.
Two tablets orally every 12 hours: one tablet tezacaftor 50mg/ivacaftor 75mg and one tablet ivacaftor 150mg, taken with fat-containing food.
None Documented
None Documented
12 hours (terminal); supports twice-daily dosing; steady-state reached in 2-3 days.
Tezacaftor: terminal half-life approximately 15 hours; ivacaftor: terminal half-life approximately 12 hours (range 9–15 hours). The half-lives support twice-daily dosing (every 12 hours) for steady state.
Primarily hepatic metabolism (CYP3A4), then biliary/fecal elimination; 88% in feces, <1% in urine as unchanged drug.
Tezacaftor is primarily metabolized, with <1% excreted unchanged in urine and 72% of the dose recovered in feces (mainly as metabolites). Ivacaftor is extensively metabolized; 87% of the dose is excreted in feces (mostly as metabolites) and <1% in urine. Biliary/fecal elimination is the major route for both.
Category C
Category C
CFTR Potentiator
CFTR Potentiator/Corrector